OptimizeRx Corp·4

Jun 10, 1:37 PM ET

Vos Ellen O'Connor 4

Research Summary

AI-generated summary

Updated

OptimizeRx (OPRX) Director Ellen O'Connor Receives RSU Award

What Happened
Ellen O'Connor, a director of OptimizeRx Corp (OPRX), received a grant of 34,517 restricted stock units (RSUs) on 2026-06-09. The RSUs were reported at $0.00 (no cash purchase); they represent a contingent right to receive shares of common stock upon vesting.

Key Details

  • Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely filing).
  • Transaction type/code: Award/Grant (A).
  • Shares/units granted: 34,517 RSUs; reported acquisition price $0.00.
  • Vesting: RSUs vest in full on the earlier of the first anniversary of the grant or the Company’s next annual meeting (per footnote).
  • Shares owned after transaction: Not specified in the provided excerpt of the filing.
  • Remarks in filing: standard disclaimer that the filer does not necessarily admit beneficial ownership for Section 16 purposes.

Context
This was a compensation award (RSUs), not an open-market purchase or sale. RSU grants are routine director/employee compensation and do not by themselves indicate buying or selling intent; value is realized when and if the units vest and convert to shares (or are settled per company policy).